PubMed:17261671 / 763-1079
Annnotations
PubMed_ArguminSci
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 0-316 | DRI_Approach | denotes | The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis. |
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T5 | 0-316 | Sentence | denotes | The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis. |
T5 | 0-316 | Sentence | denotes | The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis. |
DisGeNET
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T0 | 53-62 | gene:5465 | denotes | PPARalpha |
T1 | 300-315 | disease:C0003850 | denotes | atherosclerosis |
T2 | 53-62 | gene:5465 | denotes | PPARalpha |
T3 | 300-315 | disease:C0004153 | denotes | atherosclerosis |
T4 | 103-112 | gene:5468 | denotes | PPARgamma |
T5 | 300-315 | disease:C0003850 | denotes | atherosclerosis |
T6 | 103-112 | gene:5468 | denotes | PPARgamma |
T7 | 300-315 | disease:C0004153 | denotes | atherosclerosis |
T8 | 257-261 | gene:5465 | denotes | PPAR |
T9 | 300-315 | disease:C0003850 | denotes | atherosclerosis |
T10 | 257-261 | gene:5465 | denotes | PPAR |
T11 | 300-315 | disease:C0004153 | denotes | atherosclerosis |
R1 | T0 | T1 | associated_with | PPARalpha,atherosclerosis |
R2 | T2 | T3 | associated_with | PPARalpha,atherosclerosis |
R3 | T4 | T5 | associated_with | PPARgamma,atherosclerosis |
R4 | T6 | T7 | associated_with | PPARgamma,atherosclerosis |
R5 | T8 | T9 | associated_with | PPAR,atherosclerosis |
R6 | T10 | T11 | associated_with | PPAR,atherosclerosis |
PubmedHPO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 300-315 | HP_0002621 | denotes | atherosclerosis |
DisGeNET5_gene_disease
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
17261671-4#53#62#gene5465 | 53-62 | gene5465 | denotes | PPARalpha |
17261671-4#103#112#gene5468 | 103-112 | gene5468 | denotes | PPARgamma |
17261671-4#300#315#diseaseC0003850 | 300-315 | diseaseC0003850 | denotes | atherosclerosis |
17261671-4#300#315#diseaseC0004153 | 300-315 | diseaseC0004153 | denotes | atherosclerosis |
17261671-4#300#315#diseaseC0003850 | 300-315 | diseaseC0003850 | denotes | atherosclerosis |
17261671-4#300#315#diseaseC0004153 | 300-315 | diseaseC0004153 | denotes | atherosclerosis |
53#62#gene5465300#315#diseaseC0003850 | 17261671-4#53#62#gene5465 | 17261671-4#300#315#diseaseC0003850 | associated_with | PPARalpha,atherosclerosis |
53#62#gene5465300#315#diseaseC0004153 | 17261671-4#53#62#gene5465 | 17261671-4#300#315#diseaseC0004153 | associated_with | PPARalpha,atherosclerosis |
53#62#gene5465300#315#diseaseC0003850 | 17261671-4#53#62#gene5465 | 17261671-4#300#315#diseaseC0003850 | associated_with | PPARalpha,atherosclerosis |
53#62#gene5465300#315#diseaseC0004153 | 17261671-4#53#62#gene5465 | 17261671-4#300#315#diseaseC0004153 | associated_with | PPARalpha,atherosclerosis |
103#112#gene5468300#315#diseaseC0003850 | 17261671-4#103#112#gene5468 | 17261671-4#300#315#diseaseC0003850 | associated_with | PPARgamma,atherosclerosis |
103#112#gene5468300#315#diseaseC0004153 | 17261671-4#103#112#gene5468 | 17261671-4#300#315#diseaseC0004153 | associated_with | PPARgamma,atherosclerosis |
103#112#gene5468300#315#diseaseC0003850 | 17261671-4#103#112#gene5468 | 17261671-4#300#315#diseaseC0003850 | associated_with | PPARgamma,atherosclerosis |
103#112#gene5468300#315#diseaseC0004153 | 17261671-4#103#112#gene5468 | 17261671-4#300#315#diseaseC0004153 | associated_with | PPARgamma,atherosclerosis |
DisGeNet-2017-sample
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1817 | 53-62 | gene:5465 | denotes | PPARalpha |
T1818 | 300-315 | disease:C0003850 | denotes | atherosclerosis |
T1819 | 103-112 | gene:5468 | denotes | PPARgamma |
R1 | T1817 | T1818 | associated_with | PPARalpha,atherosclerosis |
R2 | T1817 | T1818 | associated_with | PPARalpha,atherosclerosis |
R3 | T1819 | T1818 | associated_with | PPARgamma,atherosclerosis |
R4 | T1819 | T1818 | associated_with | PPARgamma,atherosclerosis |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T5 | 0-316 | Sentence | denotes | The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis. |
T5 | 0-316 | Sentence | denotes | The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis. |